Sjoerd van Marle

611 total citations
19 papers, 481 citations indexed

About

Sjoerd van Marle is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Oncology. According to data from OpenAlex, Sjoerd van Marle has authored 19 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Pharmacology and 4 papers in Oncology. Recurrent topics in Sjoerd van Marle's work include Antifungal resistance and susceptibility (3 papers), Diabetes Treatment and Management (3 papers) and Pharmaceutical studies and practices (3 papers). Sjoerd van Marle is often cited by papers focused on Antifungal resistance and susceptibility (3 papers), Diabetes Treatment and Management (3 papers) and Pharmaceutical studies and practices (3 papers). Sjoerd van Marle collaborates with scholars based in Netherlands, United States and Switzerland. Sjoerd van Marle's co-authors include Marloes Schaddelee, John Meijer, Marcel van Gelderen, R Baughman, James Cassidy, Rita Schmitt, Cornelia Weber, Herbert Birnboeck, Herwig Eggers and J. H. G. Jonkman and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and Diabetes Obesity and Metabolism.

In The Last Decade

Sjoerd van Marle

18 papers receiving 456 citations

Peers

Sjoerd van Marle
Zhenzhen Cao China
Hung‐Jen Shih Taiwan
Hirofumi Okubo Japan
Yat‐Ching Tong Taiwan
Masashi Kubota Japan
Yun‐Ching Huang Taiwan
Thomas Mouillot France
Robert Haws United States
Zhenzhen Cao China
Sjoerd van Marle
Citations per year, relative to Sjoerd van Marle Sjoerd van Marle (= 1×) peers Zhenzhen Cao

Countries citing papers authored by Sjoerd van Marle

Since Specialization
Citations

This map shows the geographic impact of Sjoerd van Marle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sjoerd van Marle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sjoerd van Marle more than expected).

Fields of papers citing papers by Sjoerd van Marle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sjoerd van Marle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sjoerd van Marle. The network helps show where Sjoerd van Marle may publish in the future.

Co-authorship network of co-authors of Sjoerd van Marle

This figure shows the co-authorship network connecting the top 25 collaborators of Sjoerd van Marle. A scholar is included among the top collaborators of Sjoerd van Marle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sjoerd van Marle. Sjoerd van Marle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Hodges, Michael R., Susan Hazel, William G. Kramer, et al.. (2024). Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants. Antimicrobial Agents and Chemotherapy. 68(5). e0145523–e0145523. 4 indexed citations
2.
Hodges, Michael R., et al.. (2024). Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants. Antimicrobial Agents and Chemotherapy. 68(6). e0165023–e0165023. 4 indexed citations
3.
Hodges, Michael R., Pamela Wedel, Karen Joy Shaw, et al.. (2023). Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 67(4). e0162322–e0162322. 32 indexed citations
4.
Snitker, Søren, et al.. (2022). Comparison of the injection‐site experience of semaglutide in a single‐dose and a multidose pen‐injector. Diabetes Obesity and Metabolism. 24(8). 1643–1646. 4 indexed citations
5.
Ahmad, Alaa, et al.. (2022). EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects. Clinical and Translational Science. 16(2). 338–351. 4 indexed citations
6.
Snitker, Søren, et al.. (2021). Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects. Diabetes Obesity and Metabolism. 23(6). 1415–1419. 3 indexed citations
7.
8.
Cahn, Anthony, Simon T. Hodgson, Robert C. Wilson, et al.. (2013). Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study. BMC Pharmacology and Toxicology. 14(1). 40 indexed citations
9.
Lee, Jennifer, Marloes Schaddelee, Wenhui Zhang, et al.. (2012). Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder. International Journal of Clinical Pharmacology and Therapeutics. 50(11). 838–850. 42 indexed citations
10.
Krauwinkel, Walter, Jan van Dijk, Marloes Schaddelee, et al.. (2012). Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women. Clinical Therapeutics. 34(10). 2144–2160. 71 indexed citations
11.
Hashimoto, Tadashi, Katsuhiro Suzuki, Takafumi Iwatsubo, et al.. (2012). Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica. 43(6). 534–547. 9 indexed citations
12.
Peeters, Pierre, Paul Passier, Jean Smeets, et al.. (2011). Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharmaceutics & Drug Disposition. 32(3). 159–167. 46 indexed citations
13.
Marino, Mark T., Diane Costello, R Baughman, et al.. (2010). Pharmacokinetics and Pharmacodynamics of Inhaled GLP-1 (MKC253): Proof-of-Concept Studies in Healthy Normal Volunteers and in Patients With Type 2 Diabetes. Clinical Pharmacology & Therapeutics. 88(2). 243–250. 30 indexed citations
14.
Kovarik, John M., et al.. (2010). Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. International Journal of Clinical Pharmacology and Therapeutics. 48(2). 103–108. 5 indexed citations
15.
Cassidy, James, et al.. (2010). Pharmacokinetic Characterization of the Novel Pulmonary Delivery Excipient Fumaryl Diketopiperazine. Journal of Diabetes Science and Technology. 4(5). 1164–1173. 39 indexed citations
16.
Vliet, André van, et al.. (2009). Hypertensive crisis-induced electrocardiographic changes: a case series. Journal of Medical Case Reports. 3(1). 7283–7283. 5 indexed citations
17.
Marle, Sjoerd van, et al.. (2005). Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 43(6). 282–293. 11 indexed citations
18.
Weber, Cornelia, Rita Schmitt, Herbert Birnboeck, et al.. (1999). Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 39(7). 703–714. 83 indexed citations
19.
Ploeg, Rutger J., et al.. (1988). Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurologica Scandinavica. 77(3). 224–230. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhenzhen Cao Breakdown of academic impact, for papers by Hung‐Jen Shih Breakdown of academic impact, for papers by Hirofumi Okubo Breakdown of academic impact, for papers by Yat‐Ching Tong Breakdown of academic impact, for papers by Masashi Kubota Breakdown of academic impact, for papers by Yun‐Ching Huang Breakdown of academic impact, for papers by Thomas Mouillot Breakdown of academic impact, for papers by Robert Haws
Rankless by CCL
2026